Intralesional verapamil prevents the progression of Peyronie's disease.
OBJECTIVE
To define the impact of intralesional verapamil injection therapy on penile deformity in men with Peyronie's disease.


METHODS
Patients underwent a total of 6 intralesional injections of verapamil. Penile deformity was assessed at baseline and 3 months after the last intralesional injection of verapamil during penile erection after the administration of intracavernosal medication. Measurement was recorded using a goniometer at maximum penile rigidity. Endpoints included change in magnitude of curvature, stretched penile length, penetration ability, and resolution of pain.


RESULTS
Ninety-four consecutive patients met all inclusion criteria. Mean (+/- standard deviation) patient age and duration of Peyronie's disease at time of baseline deformity assessment were 44 +/- 18 years and 5.2 +/- 2.7 months, respectively. At baseline 86% had dorsal and 14% lateral curvature. The mean curvature and stretched flaccid length were 50 degrees +/- 28 degrees and 12.6 +/- 3.1 cm, respectively. At the follow-up evaluation, patients were 5.2 +/- 1.8 months after their last ILV injection and were 11.7 +/- 4.2 months after the onset of Peyronie's disease. Eighteen percent of patients had improvement of curvature, 60% were unchanged, and 22% worsened. Pain resolved in 100% of patients.


CONCLUSIONS
In response to intralesional verapamil, a minority of men experienced improvement in penile deformity; however, the majority of patients had stabilization of their deformity. This information may permit clinicians to give realistic expectations to patients considering intralesional verapamil therapy.
Bennett
Nelson E
NE
Department of Urology, Weill Medical College of Cornell University, New York, New York 10021, USA.
Guhring
Patricia
P
Mulhall
John P
JP
D000328:Adult; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage*; D014700:Verapamil / Q000008:administration & dosage*
D014665:Vasodilator Agents; D014700:Verapamil